Mania-like behavior induced by genetic dysfunction of the neuron-specific Na+,K+-ATPase α3 sodium pump

Bipolar disorder is a debilitating psychopathology with unknown etiology. Accumulating evidence suggests the possible involvement of Na+,K+-ATPase dysfunction in the pathophysiology of bipolar disorder. Here we show that Myshkin mice carrying an inactivating mutation in the neuron-specific Na+,K+-AT...

Full description

Saved in:
Bibliographic Details
Published inProceedings of the National Academy of Sciences - PNAS Vol. 108; no. 44; pp. 18144 - 18149
Main Authors Kirshenbaum, Greer S, Clapcote, Steven J, Duffy, Steven, Burgess, Christian R, Petersen, Janne, Jarowek, Karolina J, Yücel, Yeni H, Cortez, Miguel A, Snead, O. Carter III, Vilsen, Bente, Peever, John H, Ralph, Martin R, Roder, John C
Format Journal Article
LanguageEnglish
Published United States National Academy of Sciences 01.11.2011
National Acad Sciences
Subjects
Online AccessGet full text
ISSN0027-8424
1091-6490
1091-6490
DOI10.1073/pnas.1108416108

Cover

More Information
Summary:Bipolar disorder is a debilitating psychopathology with unknown etiology. Accumulating evidence suggests the possible involvement of Na+,K+-ATPase dysfunction in the pathophysiology of bipolar disorder. Here we show that Myshkin mice carrying an inactivating mutation in the neuron-specific Na+,K+-ATPase α3 subunit display a behavioral profile remarkably similar to bipolar patients in the manic state. Myshkin mice show increased Ca2+ signaling in cultured cortical neurons and phospho-activation of extracellular signal regulated kinase (ERK) and Akt in the hippocampus. The mood-stabilizing drugs lithium and valproic acid, specific ERK inhibitor SL327, rostafuroxin, and transgenic expression of a functional Na+,K+-ATPase α3 protein rescue the mania-like phenotype of Myshkin mice. These findings establish Myshkin mice as a unique model of mania, reveal an important role for Na+,K+-ATPase α3 in the control of mania-like behavior, and identify Na+,K+-ATPase α3, its physiological regulators and downstream signal transduction pathways as putative targets for the design of new antimanic therapies.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by Mordecai P. Blaustein, University of Maryland School of Medicine, Baltimore, MD, and accepted by the Editorial Board September 26, 2011 (received for review May 26, 2011)
Author contributions: G.S.K., S.J.C., O.C.S., B.V., J.H.P., M.R.R., and J.C.R. designed research; G.S.K., S.J.C., S.D., C.R.B., J.P., K.J.J., Y.H.Y., M.A.C., and M.R.R. performed research; O.C.S., B.V., G.S.K., S.J.C., C.R.B., J.P., Y.H.Y., M.A.C., and M.R.R. analyzed data; and G.S.K. and S.J.C. wrote the paper.
ISSN:0027-8424
1091-6490
1091-6490
DOI:10.1073/pnas.1108416108